PT Pyridam Farma Tbk (ISX:PYFA) Cyclically Adjusted Revenue per Share: Rp201.45 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:PYFA PT Pyridam Farma Tbk ISX:PYFA
67 GF Score
Price Rp218.00
GF Value Rp211.66
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is PT Pyridam Farma Tbk Cyclically Adjusted Revenue per Share?

PT Pyridam Farma Tbk ISX:PYFA +5.83% 67 Cyclically Adjusted Revenue per Share is Rp201.45 as of Mar. 2026. GuruFocus rates ISX:PYFA with a GF Score™ of 67/100 and a GF Value™ of Rp211.66 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PT Pyridam Farma Tbk's adjusted revenue per share for the three months ended in Mar. 2026 was Rp68.217. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is Rp201.45 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PT Pyridam Farma Tbk's average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PT Pyridam Farma Tbk was 17.70% per year. The lowest was 10.40% per year. And the median was 13.80% per year.

As of today (2026-08-06), PT Pyridam Farma Tbk's current stock price is Rp218.00. PT Pyridam Farma Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was Rp201.45. PT Pyridam Farma Tbk's Cyclically Adjusted PS Ratio of today is 1.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Pyridam Farma Tbk was 3.11. The lowest was 0.33. And the median was 1.37.


PT Pyridam Farma Tbk  (ISX:PYFA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PT Pyridam Farma Tbk's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=218.00/201.45
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Pyridam Farma Tbk was 3.11. The lowest was 0.33. And the median was 1.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PT Pyridam Farma Tbk Cyclically Adjusted Revenue per Share Related Terms


PT Pyridam Farma Tbk Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PT Pyridam Farma Tbk's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Pyridam Farma Tbk Cyclically Adjusted Revenue per Share Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.21 145.28 166.30 178.15 195.62

PT Pyridam Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 182.02 187.16 191.26 195.62 201.45

ISX:PYFA vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Pyridam Farma Tbk Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Pyridam Farma Tbk's Cyclically Adjusted PS Ratio falls into.


ISX:PYFA
67GF Score
PT Pyridam Farma Tbk ISX:PYFA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Pyridam Farma Tbk Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PT Pyridam Farma Tbk's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=68.217/136.5387*136.5387
=68.217

Current CPI (Mar. 2026) = 136.5387.

PT Pyridam Farma Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 24.256 103.212 32.088
201609 18.700 104.142 24.517
201612 22.830 105.222 29.625
201703 20.833 106.476 26.715
201706 21.954 107.722 27.827
201709 24.782 108.020 31.325
201712 21.911 109.017 27.443
201803 26.026 110.097 32.277
201806 23.288 111.085 28.624
201809 25.127 111.135 30.871
201812 26.052 112.430 31.638
201903 25.608 112.829 30.989
201906 23.091 114.730 27.480
201909 25.420 114.905 30.206
201912 25.037 115.486 29.601
202003 31.714 116.252 37.248
202006 17.067 116.630 19.980
202009 29.574 116.397 34.692
202012 32.952 117.318 38.351
202103 47.113 117.840 54.589
202106 42.169 118.184 48.718
202109 73.777 118.262 85.179
202112 89.944 119.516 102.755
202203 69.193 120.948 78.112
202206 54.037 123.322 59.828
202209 97.831 125.298 106.607
202212 66.007 126.098 71.472
202303 66.152 126.953 71.147
202306 59.688 127.663 63.838
202309 83.004 128.151 88.436
202312 72.865 129.395 76.888
202403 60.845 130.607 63.608
202406 22.754 130.792 23.754
202409 63.891 130.361 66.919
202412 67.545 131.432 70.170
202503 61.687 131.948 63.833
202506 62.291 133.241 63.833
202509 60.057 133.819 61.278
202512 53.313 135.271 53.813
202603 68.217 136.539 68.217

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of Rp201.45 mean?
PT Pyridam Farma Tbk (ISX:PYFA) has a Cyclically Adjusted Revenue per Share of Rp201.45 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Cyclically Adjusted Revenue per Share too high?
PT Pyridam Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp201.45. Overall, PT Pyridam Farma Tbk has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Cyclically Adjusted Revenue per Share of Rp201.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Cyclically Adjusted Revenue per Share is Rp201.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp211.66, compared to a current price of Rp218.00 — trading 3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is Rp201.45. PT Pyridam Farma Tbk's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Cyclically Adjusted Revenue per Share is Rp201.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be overvalued. The current stock price of Rp218.00 is trading 3% above its estimated GF Value™ of Rp211.66. GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.

Key valuation signals for ISX:PYFA:

  • Cyclically Adjusted Revenue per Share: Rp201.45
  • GF Value™: Rp211.66 vs. price of Rp218.00 (3% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Pyridam Farma Tbk Business Description

Address Jl. Jenderal Sudirman Kav. 21, Sinar Mas Land Plaza Sudirman 12th Floor, RT 10/RW 01 Kuningan, Karet, Jakarta Selatan, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
67GF Score

Get the complete analysis for ISX:PYFA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp218.00
Price
Rp211.66
GF Value